Study protocol of an open-label, single arm phase II trial investigating the efficacy and safety of Trifluridine/Tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma (TRITICC)

BACKGROUND: The prognosis of patients with advanced biliary tract cancer (BTC) who have progressed on gemcitabine plus cisplatin is dismal. Trifluridine/tipiracil (FTD/TPI) and irinotecan have proven efficacy in different gastrointestinal malignancies. We therefore hypothesized that this combination...

Descripción completa

Detalles Bibliográficos
Autores principales: Kehmann, Linde, Berres, Marie-Luise, Gonzalez-Carmona, Maria, Modest, Dominik P., Mohr, Raphael, Wree, Alexander, Venerito, Marino, Strassburg, Christian, Keitel, Verena, Trautwein, Christian, Luedde, Tom, Roderburg, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10204189/
https://www.ncbi.nlm.nih.gov/pubmed/37217885
http://dx.doi.org/10.1186/s12885-023-10972-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10204189/
https://www.ncbi.nlm.nih.gov/pubmed/37217885
http://dx.doi.org/10.1186/s12885-023-10972-6

Ejemplares similares